Edition:
India

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

1.64USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$1.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,103
52-wk High
$6.43
52-wk Low
$1.45

Chart for

About

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and... (more)
No analyst recommendations are available for .

Overall

Beta: -0.75
Market Cap(Mil.): $45.06
Shares Outstanding(Mil.): 9.95
Dividend: --
Yield (%): --

Financials

  KOOL.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -4.38 -- --
ROI: -67.06 14.84 14.38
ROE: -92.20 16.34 16.07

BRIEF-Cesca Therapeutics Entered Amendment To Revolving Line Of Credit Facility

* CESCA THERAPEUTICS SAYS ON APRIL 16, ENTERED AMENDMENT TO ITS REVOLVING LINE OF CREDIT FACILITY - SEC FILING

18 Apr 2018

BRIEF-Cesca Therapeutics Announces First Evaluation Agreement With A Leading U.S. Academic Research Institution For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES FIRST EVALUATION AGREEMENT WITH A LEADING U.S. ACADEMIC RESEARCH INSTITUTION FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING

17 Apr 2018

BRIEF-Cesca Therapeutics Announces Registered Direct Offering

* CESCA THERAPEUTICS INC - ‍PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS TO 609,636 SHARES OF STOCK AT A PURCHASE PRICE OF $2.27 PER SHARE​ Source text for Eikon: Further company coverage:

26 Mar 2018

BRIEF-Cesca Subsidiary Expands Into CAR-T Related Contract Development And Manufacturing

* CESCA’S DEVICE SUBSIDIARY, THERMOGENESIS, EXPANDS INTO CAR-T RELATED CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) SERVICES

14 Mar 2018

BRIEF-Cesca Therapeutics Files For Common Stock Offering Of Up To $15 Mln

* FILES FOR COMMON STOCK OFFERING OF UP TO $15 MILLION - SEC FILING Source text: (http://bit.ly/2E1uKu2) Further company coverage:

24 Jan 2018

BRIEF-Cesca Therapeutics Announces Proposed Public Offering Of Common Stock

* CESCA THERAPEUTICS INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

29 Nov 2017

BRIEF-Cesca Therapeutics appoints Joe Balagot as senior vice president of corporate development

* Cesca Therapeutics appoints healthcare investment banking veteran Joe E. Balagot as senior vice president of corporate development Source text for Eikon: Further company coverage:

22 Nov 2017

BRIEF-Cesca Therapeutics reports quarterly loss per share $0.24

* Cesca Therapeutics announces financial results for the three months ended September 30, 2017 and provides corporate update

15 Nov 2017

Earnings vs. Estimates